Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is malignant solitary fibrous tumor?
Solitary fibrous tumor is a soft-tissue tumor that arises from fibrous (connective) tissue and can appear almost anywhere — the lining of the lungs (pleura), the abdomen and pelvis, the limbs, the head and neck, or the lining of the brain (where it was once called hemangiopericytoma). Most solitary fibrous tumors are benign and cured by surgery, but a subset are malignant: they grow faster, have more dividing cells under the microscope, and can both come back locally and spread to distant organs such as the lungs, liver, and bone. All solitary fibrous tumors, benign or malignant, share the same molecular signature — a NAB2-STAT6 gene fusion — which pathologists detect with a STAT6 stain to confirm the diagnosis. A key feature of even the malignant form is that recurrence or spread can happen very late, sometimes a decade or two after the original tumor, so lifelong follow-up matters.
The main types
Doctors group malignant solitary fibrous tumor by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Malignant (high-risk) solitary fibrous tumor | Defined by features such as a high number of dividing cells, large size, older patient age, and dead tissue (necrosis) within the tumor — the combination that predicts aggressive behavior. |
| Dedifferentiated solitary fibrous tumor | The most aggressive form, where part of the tumor transforms into a high-grade sarcoma; carries the highest risk of spread. |
| Meningeal solitary fibrous tumor (former hemangiopericytoma) | Arises on the lining of the brain or spinal cord; behaves like the malignant type, with a notable tendency to recur and occasionally spread outside the nervous system. |
Staging, in plain terms
Solitary fibrous tumors are not graded by ordinary TNM. Instead, doctors use risk models that combine patient age, tumor size, the number of dividing cells (mitotic rate), and whether there is necrosis to estimate the chance of recurrence or spread, sorting tumors into low-, intermediate-, and high-risk groups.
| Risk-model based (not a single TNM stage) | What it generally means |
|---|---|
| Low risk | Small tumors with few dividing cells in younger patients. Usually cured by complete surgery, though follow-up is still recommended. |
| Intermediate / high risk (malignant) | Larger tumors, more dividing cells, necrosis, or older age. These are the malignant tumors that warrant surgery plus radiation and close surveillance. |
| Metastatic | Spread to the lungs, liver, or bone — which can occur years after the original tumor. Often slow-growing, allowing targeted local treatment of individual deposits. |
The standard of care
Malignant Solitary Fibrous Tumor is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery (the cornerstone)
Complete removal of the tumor with a clear margin is the main treatment and offers the best chance of cure, wherever the tumor is located.
Radiation therapy
Added before or after surgery for malignant, large, or incompletely removed tumors, and for meningeal tumors after surgery, to reduce the high risk of local recurrence.
Stereotactic radiosurgery for brain/spine tumors
For meningeal solitary fibrous tumors, focused radiosurgery (such as Gamma Knife) is often used after surgery to improve long-term local control.
Antiangiogenic drugs for advanced disease
Because these tumors are rich in blood vessels, drugs that block blood-vessel growth (such as pazopanib, sunitinib, or temozolomide-bevacizumab) can control metastatic disease; chemotherapy has limited effect.
How radiation treatment works
Radiation damages the DNA inside tumor cells so they can no longer divide, while healthy tissue repairs itself. In malignant solitary fibrous tumor, radiation lowers the risk of the tumor returning after surgery and, as precise radiosurgery or SBRT, can control tumors on the lining of the brain or individual metastases. It is given as short, painless daily sessions (or a few sessions for radiosurgery) and leaves no radioactivity in your body, so you stay safe to be around family throughout treatment.
The main ways radiation is delivered for malignant solitary fibrous tumor:
Intensity-modulated / image-guided radiation (IMRT/IGRT)
Precisely shaped x-ray beams deliver a high dose to the tumor bed while protecting nearby organs, useful given how varied these tumors' locations are.
Stereotactic radiosurgery / SBRT
Highly focused, high-dose beams in one or a few sessions treat meningeal tumors and individual lung or bone metastases with millimeter precision.
Proton therapy (selected cases)
Protons reduce dose to surrounding tissue for tumors near the spine, brain, or other sensitive structures.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Risk models predict late recurrence: Validated models combining age, size, mitotic count, and necrosis reliably identify malignant tumors most likely to recur or spread, guiding decisions about radiation and surveillance.[1]
Demicco and other solitary-fibrous-tumor risk-stratification studies
NAB2-STAT6 fusion confirms diagnosis: The STAT6 stain, reflecting the universal NAB2-STAT6 fusion, has made diagnosis far more reliable and unified the former 'hemangiopericytoma' with solitary fibrous tumor.[2]
Soft-tissue tumor molecular pathology reviews
Antiangiogenic therapy for metastatic disease: Trials of pazopanib and other antiangiogenic agents show meaningful disease control in advanced solitary fibrous tumor, which responds poorly to conventional chemotherapy.[3]
Sarcoma cooperative-group and phase II trials
Common questions
My tumor was called a solitary fibrous tumor — is it cancer? Most solitary fibrous tumors are benign and cured by surgery. Yours is the malignant form, which means it has features that make recurrence or spread more likely, so it's treated more thoroughly — usually surgery plus radiation — and followed closely.
Why do I need follow-up for so long? Solitary fibrous tumors are well known for coming back or spreading very late — sometimes 10 to 20 years later. Long-term imaging lets your team catch any recurrence early, when it can often be treated with surgery or focused radiation.
Is this the same as the old 'hemangiopericytoma'? Yes. Tumors once called hemangiopericytoma — especially those on the lining of the brain — are now recognized as solitary fibrous tumors because they share the same NAB2-STAT6 gene fusion. The change reflects better understanding, not a different disease.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- Demicco and other solitary-fibrous-tumor risk-stratification studies (no indexed identifier — see your care team) ↩
- Soft-tissue tumor molecular pathology reviews (no indexed identifier — see your care team) ↩
- Sarcoma cooperative-group and phase II trials (no indexed identifier — see your care team) ↩